Why is nonadherence to cancer screening associated with increased mortality?
Menée aux Etats-Unis à l'aide des données du "National Death Index" et de données portant sur 64 567 personnes incluses dans l'essai américain "PLCO" (âge moyen : 62,3 ans ; durée de suivi : 10 ans), cette étude analyse l'association entre la non adhésion aux examens de dépistage de certains cancers (cancer colorectal, cancer de la prostate, du poumon ou de l'ovaire) et la mortalité par autres causes
In this issue of JAMA Internal Medicine, Pierre-Victor and Pinsky1 use data from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening trial2 to demonstrate an association between lack of adherence to cancer screening and increased mortality from causes not related to the screening. Participants in the PLCO Cancer Screening trial were 55 to 74 years of age and generally healthy. At trial entry, participants of both sexes in the screening arm were asked to undergo chest radiographs for lung cancer and flexible sigmoidoscopy for colon cancer, men were asked to undergo prostate-specific antigen tests and digital rectal examinations for prostate cancer, and women were asked to undergo cancer antigen 125 tests and transvaginal ultrasonography for ovarian cancer. Those randomized to the control group received usual care.
JAMA Internal Medicine , éditorial, 2018